Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease

DOI: https://doi.org/10.58347/tml.2024.1697b
2024-03-04
Abstract:The FDA has approved the sodium/hydrogen exchanger 3 (NHE3) inhibitor tenapanor (Xphozah – Ardelyx) to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy when phosphate binders are ineffective or as monotherapy when phosphate binders cannot be tolerated. Tenapanor is the first NHE3 inhibitor to be approved in the US for hyperphosphatemia. It was previously approved as Ibsrela to treat irritable bowel syndrome with constipation (IBS-C).
pharmacology & pharmacy
What problem does this paper attempt to address?